# US 2023/0266331 A1 · Use of antigen combination for detecting autoantibodies in lung cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0266331 A1
- Document ID: US20230266331A1
- Status: Published application
- Kind: A1
- Application number: 18/005,568
- Filed: 2021-07-14
- Published: 2023-08-24
- Earliest claimed: 2020-07-14
- Assignees: OncImmune Ltd.
- Applicants: Oncimmune Limited
- Inventors: Andrea MURRAY; Jared ALLEN; Philip GUNNING; Isabel MACDONALD; Celine PARSY-KOWALSKA
- Web page: https://patentgrep.com/patent/US20230266331A1

## CPC

- G01N 33/57585: {involving compounds identifiable in body fluids}
- G01N 33/5752: of the lungs
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 2333/4748: p53
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates generally to the field of antibody detection, and in particular relates to methods involving the detection of autoantibodies relating to lung cancer in a sample comprising patient bodily fluid. In particular, the present invention relates to a method of detecting lung cancer in a mammalian subject by detecting three or more autoantibodies in a test sample, wherein three of the autoantibodies are immunologically specific for the tumour marker antigens p53, SSX1, and either p62 or KOC. The invention also relates to in vitro methods of determining an autoantibody profile, methods of diagnosing and treating lung cancer, methods of predicting response to a lung cancer treatment, use of a panel of three or more tumour marker antigens for the detection of lung cancer, and kits for the detection of autoantibodies.

## Claims

### Claim 1

A method of detecting lung cancer in a mammalian subject by detecting three or more autoantibodies in a test sample comprising a bodily fluid from the mammalian subject, wherein three of the autoantibodies are immunologically specific for the tumour marker antigens p53, SSX1 and either p62 or KOC, and wherein the method comprises the steps of:
(a) contacting the test sample with a panel of three or more tumour marker antigens of which three of the tumour marker antigens are p53, SSX1, and either p62 or KOC; and
(b) determining the presence or absence of complexes of the tumour marker antigens bound to autoantibodies present in the test sample,
wherein the presence of complexes containing at least p53, SSX1, and either p62 or KOC is indicative of the presence of lung cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the panel of three or more tumour marker antigens comprises p53, SSX1, and p62, and the presence of complexes containing at least p53, SSX1, and p62 is indicative of the presence of lung cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the panel of three or more tumour marker antigens comprises p53, SSX1, and KOC, and the presence of complexes containing at least p53, SSX1, and KOC is indicative of the presence of lung cancer.

### Claim 4 (depends on 1)

The method of claim 1, wherein the panel of three or more tumour marker antigens comprises p53, SSX1, and p62 and/or KOC, and one or more tumour marker antigens selected from the group consisting of HuD, MAGE A4, SOX2, NY-ESO-1, CAGE, CK20, GBU4-5, p53-95, CK8, KRAS-G13C/Q61H, ALDH1, p16, Lmyc2, and α-enolase-1.

### Claim 5 (depends on 1)

The method claim 1, wherein four or more autoantibodies are detected, wherein the method comprises the step of (a) contacting the test sample with a panel of four or more tumour marker antigens of which four of the tumour marker antigens are p53, SSX1, p62 or KOC, and HuD, and wherein the presence of complexes containing at least p53, SSX1, p62 or KOC, and HuD is indicative of the presence of lung cancer.

### Claim 6 (depends on 1)

The method of claim 1, wherein five or more autoantibodies are detected, wherein the method comprises the step of (a) contacting the test sample with a panel of five or more tumour marker antigens of which five of the tumour marker antigens are p53, SSX1, p62 or KOC, HuD, and MAGE A4, and wherein the presence of complexes containing at least p53, SSX1, p62 or KOC, HuD and MAGE A4 is indicative of the presence of lung cancer.

### Claim 7 (depends on 6)

The method of claim 6, wherein the panel of five or more tumour marker antigens comprises p53, SSX1, p62 and/or KOC, HuD, and MAGE A4, and one or more tumour marker antigens selected from the group consisting of SOX2, NY-ESO-1, CAGE, CK20, GBU4-5, p53-95, CK8, KRAS-G13C/Q61H, ALDH1, p16, Lmyc2, and α-enolase-1.

### Claim 8 (depends on 1)

The method of claim 1, wherein the panel of tumour marker antigens comprises or consists of one of the groups of tumour marker antigens selected from:
(i) p53, SSX1, p62, HuD, MAGE A4, SOX2, CAGE;
(ii) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CK20;
(iii) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CAGE;
(iv) p53, SSX1, p62, HuD, MAGE A4, SOX2, CAGE, CK20;
(v) p53, SSX1, p62, HuD, MAGE A4, NY-ESO-1, CAGE, CK20;
(vi) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CAGE, CK20;
(vii) p53, SSX1, p62, HuD, MAGE A4, SOX2, CK20, CK8, KRAS-G13C/Q61H;
(viii) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CK20, CK8, P53-95, KRAS-G13C/Q61H;
(ix) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CAGE, CK20, CK8, KRAS-G13C/Q61H;
(x) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CAGE, GBU4-5, CK8, KRAS-G13C/Q61H;
(xi) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, SOX2, ALDH1, p16;
(xii) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, GBU4-5;
(xiii) p53, SSX1, p62, KOC, CAGE, HuD, NY-ESO-1, p16, GBU4-5;
(xiv) p53, SSX1, p62, KOC, CAGE, HuD, NY-ESO-1, SOX2, p16, α-enolase-1;
(xv) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, SOX2, ALDH1;
(xvi) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, ALDH1, p16, α-enolase-1, Lmyc2;
(xvii) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, SOX2, p16;
(xviii) p53, SSX1, p62, CAGE, NY-ESO-1, p16;
(xix) p53, SSX1, p62, NY-ESO-1, SOX2, α-enolase-1;
(xx) p53, SSX1, p62, KOC, HuD, NY-ESO-1, SOX2, α-enolase-1;
(xxi) p53, SSX1, p62, NY-ESO-1, SOX2, ALDH1, p16;
(xxii) p53, SSX1, p62, KOC, CAGE, SOX2, α-enolase-1;
(xxiii) p53, SSX1, KOC, CAGE, HuD, NY-ESO-1, SOX2, ALDH1, p16;
(xxiv) p53, SSX1, KOC, HuD, NY-ESO-1, SOX2, p16, GBU4-5;
(xxv) p53, SSX1, KOC, CAGE, HuD, SOX2, GBU4-5, α-enolase-1, Lmyc2;
(xxvi) p53, SSX1, KOC, CAGE, HuD, p16, GBU4-5; and
(xxvii) p53, SSX1, KOC, CAGE, SOX2, ALDH1, GBU4-5, Lmyc2.

### Claim 9 (depends on 1)

The method of claim 1, further comprising the step of:
(c) detecting the amount of specific binding between the tumour marker antigen and autoantibodies present in the test sample,
wherein the presence or absence of the autoantibody is based upon a comparison between the amount of specific binding observed and a pre-determined cut-off value.

### Claim 10 (depends on 1)

The method of claim 1, wherein the tumour marker antigen is provided in a plurality of different amounts, and wherein the method comprises the steps of:
(a) contacting the test sample with a plurality of different amounts of the tumour marker antigen;
(b) determining the presence or absence of complexes of the tumour marker antigen bound to autoantibodies present in the test sample;
(c) detecting the amount of specific binding between the tumour marker antigen and the autoantibodies;
(d) plotting or calculating a curve of the amount of the specific binding versus the amount of tumour marker antigen for each amount of tumour marker antigen used in step (a); and
(e) determining the presence or absence of the autoantibody based upon the amount of specific binding between the tumour marker antigen and the autoantibody at each different amount of tumour marker antigen used.

### Claim 11 (depends on 10)

The method of claim 10, wherein the method further comprises the steps of:
(d1) calculating a secondary curve parameter from the curve plotted or calculated in step (d); and
(e) determining the presence or absence of the autoantibody based upon a combination of:
(i) the amount of specific binding between the autoantibody and the tumour marker antigen determined in step (b); and
(ii) the secondary curve parameter determined in step (d1).

### Claim 12

An in vitro method of determining an autoantibody profile of an individual suffering from lung cancer by detecting three or more autoantibodies in a test sample comprising a bodily fluid from the mammalian subject, wherein three of the autoantibodies are immunologically specific for the tumour marker antigens p53, SSX1, and either p62 or KOC, which method comprises the steps of:
a) contacting the test sample with a panel of three or more tumour marker antigens of which three of the tumour marker antigens are p53, SSX1, and either p62 or KOC; and
b) determining the presence or absence of complexes of the tumour marker antigens bound to autoantibodies present in the test sample, wherein the method is repeated to build up a profile of autoantibody production.

### Claim 13

A method of diagnosing and treating lung cancer in a mammalian subject by detecting three or more autoantibodies in a test sample comprising a bodily fluid from the mammalian subject, wherein three of the autoantibodies are immunologically specific for the tumour marker antigens p53, SSX1, and either p62 or KOC, which method comprises the steps of:
(a) contacting the test sample with a panel of three or more tumour marker antigens of which three of the tumour marker antigens are p53, SSX1, and either p62 or KOC;
(b) determining the presence or absence of complexes of the tumour marker antigens bound to autoantibodies present in the test sample;
(c) diagnosing the subject with lung cancer when complexes containing at least the tumour marker antigens p53, SSX1, and either p62 or KOC bound to autoantibodies present in the test sample are detected; and
(d) administering a lung cancer treatment to the diagnosed subject.

### Claim 14

A method of predicting response to a lung cancer treatment, the method comprising detecting three or more autoantibodies in a test sample comprising a bodily fluid from a mammalian subject, wherein three of the autoantibodies are immunologically specific for the tumour marker antigens p53, SSX1, and either p62 or KOC, which method comprises the steps of:
(a) contacting the test sample with a panel of three or more tumour marker antigens of which three of the tumour marker antigens are p53, SSX1, and either p62 or KOC;
(b) determining the presence or absence of complexes of the tumour marker antigens bound to autoantibodies present in the test sample;
(c) detecting the amount of specific binding between the tumour marker antigens and autoantibodies present in the test sample; and
(d) comparing the amount of specific binding between the tumour marker antigens and the autoantibodies with a previously established relationship between the amount of binding and the likely outcome of treatment,
wherein a change in the amount of specific binding, when compared to controls, predicts that the patient will or will not respond to the lung cancer treatment.

### Claim 15 (depends on 13)

The method of claim 13, wherein the lung cancer treatment is selected from the group consisting of surgery, video-assisted thoracoscopic surgery, radiotherapy, chemotherapy, immunotherapy, radiofrequency ablation, biological therapy, cryotherapy and photodynamic therapy.

### Claim 16

Use of a panel of three or more tumour marker antigens for the detection of lung cancer in a mammalian subject by detecting autoantibodies immunologically specific for p53, SSX1, and either p62 or KOC, in a test sample comprising a bodily fluid from the mammalian subject.

### Claim 17 (depends on 12)

The method of claim 12, wherein the panel of three or more tumour marker antigens comprises p53, SSX1, and p62.

### Claim 18 (depends on 12)

The method of claim 12, wherein the panel of three or more tumour marker antigens comprises p53, SSX1, and KOC.

### Claim 19 (depends on 12)

The method of claim 12, wherein the panel of three or more tumour marker antigens comprises p53, SSX1, and p62 and/or KOC, and one or more tumour marker antigens selected from the group consisting of HuD, MAGE A4, SOX2, NY-ESO-1, CAGE, CK20, GBU4-5, p53-95, CK8, KRAS-G13C/Q61H, ALDH1, p16, Lmyc2, and α-enolase-1.

### Claim 20 (depends on 12)

The method of claim 12, wherein four or more autoantibodies are detected, wherein the method or use comprises contacting the test sample with a panel of four or more tumour marker antigens of which four of the tumour marker antigens are p53, SSX1, p62 or KOC, and HuD, and wherein the presence of at least complexes containing p53, SSX1, p62 or KOC, and HuD is detected.

### Claim 21 (depends on 12)

The method of claim 12, wherein five or more autoantibodies are detected, wherein the method or use comprises contacting the test sample with a panel of five or more tumour marker antigens of which five of the tumour marker antigens are p53, SSX1, p62 or KOC, HuD and MAGE A4, and wherein the presence of at least complexes containing p53, SSX1, p62 or KOC, HuD and MAGE A4 is detected.

### Claim 22 (depends on 21)

The method or use of claim 21, wherein the panel of five or more tumour marker antigens comprises p53, SSX1, p62 and/or KOC, HuD, and MAGE A4, and one or more tumour marker antigens selected from the group consisting of SOX2, NY-ESO-1, CAGE, CK20, GBU4-5, p53-95, CK8, KRAS-G13C/Q61H, ALDH1, p16, Lmyc2, and α-enolase-1.

### Claim 23 (depends on 12)

The method of claim 12, wherein the panel of tumour marker antigens comprises or consists of one of the groups of tumour marker antigens selected from:
(i) p53, SSX1, p62, HuD, MAGE A4, SOX2, CAGE;
(ii) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CK20;
(iii) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CAGE;
(iv) p53, SSX1, p62, HuD, MAGE A4, SOX2, CAGE, CK20;
(v) p53, SSX1, p62, HuD, MAGE A4, NY-ESO-1, CAGE, CK20;
(vi) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CAGE, CK20;
(vii) p53, SSX1, p62, HuD, MAGE A4, SOX2, CK20, CK8, KRAS-G13C/Q61H;
(viii) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CK20, CK8, p53-95, KRAS-G13C/Q61H;
(ix) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CAGE, CK20, CK8, KRAS-G13C/Q61H;
(x) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CAGE, GBU4-5, CK8, KRAS-G13C/Q61H;
(xi) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, SOX2, ALDH1, p16;
(xii) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, GBU4-5;
(xiii) p53, SSX1, p62, KOC, CAGE, HuD, NY-ESO-1, p16, GBU4-5;
(xiv) p53, SSX1, p62, KOC, CAGE, HuD, NY-ESO-1, SOX2, p16, α-enolase-1;
(xv) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, SOX2, ALDH1;
(xvi) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, ALDH1, p16, α-enolase-1, Lmyc2;
(xvii) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, SOX2, p16;
(xviii) p53, SSX1, p62, CAGE, NY-ESO-1, p16;
(xix) p53, SSX1, p62, NY-ESO-1, SOX2, α-enolase-1;
(xx) p53, SSX1, p62, KOC, HuD, NY-ESO-1, SOX2, α-enolase-1;
(xxi) p53, SSX1, p62, NY-ESO-1, SOX2, ALDH1, p16;
(xxii) p53, SSX1, p62, KOC, CAGE, SOX2, α-enolase-1;
(xxiii) p53, SSX1, KOC, CAGE, HuD, NY-ESO-1, SOX2, ALDH1, p16;
(xxiv) p53, SSX1, KOC, HuD, NY-ESO-1, SOX2, p16, GBU4-5;
(xxv) p53, SSX1, KOC, CAGE, HuD, SOX2, GBU4-5, α-enolase-1, Lmyc2;
(xxvi) p53, SSX1, KOC, CAGE, HuD, p16, GBU4-5; and
(xxvii) p53, SSX1, KOC, CAGE, SOX2, ALDH1, GBU4-5, Lmyc2.

### Claim 24

A kit for the detection of autoantibodies in a test sample comprising a bodily fluid from a mammalian subject comprising:
(a) a panel of three or more tumour marker antigens of which three of the tumour marker antigens are p53, SSX1, and either p62 or KOC; and
(b) a reagent capable of detecting complexes of the tumour marker antigens bound to autoantibodies present in the test sample.

### Claim 25 (depends on 24)

The kit of claim 24, wherein the panel of three or more tumour marker antigens comprises p53, SSX1, and p62.

### Claim 26 (depends on 24)

The kit of claim 24, wherein the panel of three or more tumour marker antigens comprises p53, SSX1, and KOC.

### Claim 27 (depends on 24)

The kit of claim 24, further comprising:
(c) means for contacting the tumour marker antigens with a test sample comprising a bodily fluid from a mammalian subject.

### Claim 28 (depends on 27)

The kit of claim 27, wherein the means for contacting the tumour marker antigens with a test sample comprising a bodily fluid from a mammalian subject comprises the tumour marker antigens immobilised on a chip, slide, plate, wells of a microtitre plate, bead, membrane or nanoparticle.

### Claim 29 (depends on 24)

The kit of claim 24, wherein the panel of three or more tumour marker antigens comprises p53, SSX1, and p62 and/or KOC and one or more tumour marker antigens selected from the group consisting of HuD, MAGE A4, SOX2, NY-ESO-1, CAGE, CK20, GBU4-5, p53-95, CK8, KRAS-G13C/Q61H, ALDH1, p16, Lmyc2, and α-enolase-1.

### Claim 30 (depends on 24)

The kit of claim 24, comprising a panel of four or more tumour marker antigens of which four of the tumour marker antigens are p53, SSX1, p62 or KOC, and HuD.

### Claim 31 (depends on 24)

The kit of claim 24, comprising a panel of five or more tumour marker antigens of which five of the tumour marker antigens are p53, SSX1, p62 or KOC, HuD, and MAGE A4.

### Claim 32 (depends on 31)

The kit of claim 31, wherein the panel of five or more tumour marker antigens comprises p53, SSX1, p62 and/or KOC, HuD and MAGE A4, and one or more tumour marker antigens selected from the group consisting of SOX2, NY-ESO-1, CAGE, CK20, GBU4-5, p53-95, CK8, KRAS-G13C/Q61H, ALDH1, p16, Lmyc2, and α-enolase-1.

### Claim 33 (depends on 31)

The kit of claim 31, wherein the panel of tumour marker antigens comprises or consists of one of the groups of tumour marker antigens selected from:
(i) p53, SSX1, p62, HuD, MAGE A4, SOX2, CAGE;
(ii) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CK20;
(iii) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CAGE;
(iv) p53, SSX1, p62, HuD, MAGE A4, SOX2, CAGE, CK20;
(v) p53, SSX1, p62, HuD, MAGE A4, NY-ESO-1, CAGE, CK20;
(vi) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CAGE, CK20;
(vii) p53, SSX1, p62, HuD, MAGE A4, SOX2, CK20, CK8, KRAS-G13C/Q61H;
(viii) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CK20, CK8, p53-95, KRAS-G13C/Q61H;
(ix) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CAGE, CK20, CK8, KRAS-G13C/Q61H;
(x) p53, SSX1, p62, HuD, MAGE A4, SOX2, NY-ESO-1, CAGE, GBU4-5, CK8, KRAS-G13C/Q61H;
(xi) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, SOX2, ALDH1, p16;
(xii) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, GBU4-5;
(xiii) p53, SSX1, p62, KOC, CAGE, HuD, NY-ESO-1, p16, GBU4-5;
(xiv) p53, SSX1, p62, KOC, CAGE, HuD, NY-ESO-1, SOX2, p16, α-enolase-1;
(xv) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, SOX2, ALDH1;
(xvi) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, ALDH1, p16, α-enolase-1, Lmyc2;
(xvii) p53, SSX1, p62, CAGE, HuD, NY-ESO-1, SOX2, p16;
(xviii) p53, SSX1, p62, CAGE, NY-ESO-1, p16;
(xix) p53, SSX1, p62, NY-ESO-1, SOX2, α-enolase-1;
(xx) p53, SSX1, p62, KOC, HuD, NY-ESO-1, SOX2, α-enolase-1;
(xxi) p53, SSX1, p62, NY-ESO-1, SOX2, ALDH1, p16;
(xxii) p53, SSX1, p62, KOC, CAGE, SOX2, α-enolase-1;
(xxiii) p53, SSX1, KOC, CAGE, HuD, NY-ESO-1, SOX2, ALDH1, p16;
(xxiv) p53, SSX1, KOC, HuD, NY-ESO-1, SOX2, p16, GBU4-5;
(xxv) p53, SSX1, KOC, CAGE, HuD, SOX2, GBU4-5, α-enolase-1, Lmyc2;
(xxvi) p53, SSX1, KOC, CAGE, HuD, p16, GBU4-5; and
(xxvii) p53, SSX1, KOC, CAGE, SOX2, ALDH1, GBU4-5, Lmyc2.

### Claim 34 (depends on 24)

The kit of claim 24 for the detection of lung cancer.

### Claim 35 (depends on 1)

The method of claim 1, wherein the tumour marker antigen is a naturally occurring protein or polypeptide, a recombinant protein or polypeptide, a synthetic protein or polypeptide, a synthetic peptide, a peptide mimetic, a polysaccharide or a nucleic acid.

### Claim 36 (depends on 1)

The method of claim 1, wherein the bodily fluid is selected from the group consisting of plasma, serum, whole blood, urine, sweat, lymph, faeces, cerebrospinal fluid, ascites fluid, pleural effusion, seminal fluid, sputum, nipple aspirate, post-operative seroma, saliva, amniotic fluid, tears and wound drainage fluid.

### Claim 37

A method of detecting lung cancer in a mammalian subject by detecting an autoantibody in a test sample comprising a bodily fluid from the mammalian subject, wherein the autoantibody is immunologically specific for a tumour marker antigen selected from the group consisting of p53, SSX1, SOX2, GBU4-5, HuD, p53-95 and CK8, and wherein the method comprises the steps of:
(a) contacting the test sample with a tumour marker antigen selected from the group consisting of p53, SSX1, SOX2, GBU4-5, HuD, p53-95 and CK8; and
(b) determining the presence or absence of complexes of the tumour marker antigen bound to autoantibodies present in the test sample,
wherein the presence of said complexes is indicative of the presence of lung cancer.

### Claim 38 (depends on 37)

The method of claim 37, wherein two, three, four, five, six, seven or more autoantibodies are detected, and the method comprises the step of
(a) contacting the test sample with a panel of at least two or more tumour marker antigens wherein at least two of the tumour marker antigens are selected from the group consisting of p53, SSX1, SOX2, GBU4-5, HuD, p53-95 and CK8, wherein the presence of complexes containing at least two of the tumour marker antigens selected from the group consisting of p53, SSX1, SOX2, GBU4-5, HuD, p53- and CK8 is indicative of the presence of lung cancer.

### Claim 39 (depends on 37)

The method of claim 37, wherein seven or more autoantibodies are detected, and the method comprises the step of (a) contacting the test sample with a panel of seven or more tumour marker antigens of which seven of the tumour marker antigens are p53, SSX1, SOX2, GBU4-5, HuD, p53-95 and CK8,
wherein the presence of complexes containing at least one tumour marker antigens selected from the group consisting of p53, SSX1, SOX2, GBU4-5, HuD, p53-95 and CK8 is indicative of the presence of lung cancer.

### Claim 40 (depends on 39)

The method of claim 39, wherein the presence of complexes containing at least p53, SSX1, SOX2, GBU4-5, HuD, p53-95 and CK8 is indicative of the presence of lung cancer.

### Claim 41

A kit for the detection of autoantibodies in a test sample comprising a bodily fluid from a mammalian subject comprising:
(a) a panel of two or more tumour marker antigens of which at least two of the tumour marker antigens are selected from the group consisting of p53, SSX1, SOX2, GBU4-5, HuD, p53-95 and CK8; and
(b) a reagent capable of detecting complexes of the tumour marker antigens bound to autoantibodies present in the test sample.

### Claim 42

A kit for the detection of autoantibodies in a test sample comprising a bodily fluid from a mammalian subject comprising:
(a) a panel of seven or more tumour marker antigens of which seven of the tumour marker antigens are p53, SSX1, SOX2, GBU4-5, HuD, p53-95 and CK8; and
(b) a reagent capable of detecting complexes of the tumour marker antigens bound to autoantibodies present in the test sample.

### Claim 43

(canceled)
